News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24
ESMO/X
Oct 14, 2024, 12:36

Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24

The European Society for Medical Oncology (ESMO) shared a post on X:

“At ESMO24, updated data of KEYNOTE-716 and CheckMate 76K studies confirm the key role of anti-programmed cell death protein 1 (PD-1)-based immunotherapy in the adjuvant setting for patients with melanoma.”

Read further.

More posts featuring ESMO.

cancer CheckMate 76K ESMO ESMO24 KEYNOTE-716 Melanoma OncoDaily Oncology The European Society for Medical Oncology
Special Coverage
Science
Dec 30, 2024, 08:49
Alessio Cortellini: Strength lies in collaboration
Science
Dec 30, 2024, 08:35
Are PPIs beneficial or harmful for stress ulcer prophylaxis in mechanically ventilated patients? - NEJM Group
Blog
Dec 30, 2024, 07:41
Antonio M. Grimaldi: Next Generation Sequencing diagnostics will soon be available at San Giovanni Addolorata Hospital, Benevento
Blog
Dec 30, 2024, 07:37
Douglas Flora: Deeply inspired by the progress made at St. Elizabeth Healthcare
Blog
Dec 30, 2024, 07:34
National Center for Cancer Immune Therapy of Denmark at ESMO Immuno-Oncology Congress 2024
Blog
Dec 30, 2024, 07:29
Don't let holiday stress steal your joy - St. Elizabeth Healthcare
Insight
Dec 30, 2024, 07:26
Self-referral for lung cancer tests would be a step in the right direction
Insight
Dec 30, 2024, 07:21
Survivorship Research for People Living with Advanced and Metastatic Cancers
Insight
Dec 30, 2024, 07:19
Drew Moghanaki: The VA in San Antonio has a new opening for a radiation oncologist
Insight
Dec 30, 2024, 06:48
Udhayvir Grewal: Excellent paper on the performance of the NETPET score
Insight
Dec 30, 2024, 06:41
Tom Powles: TIGIT and LAG3 targets have been explored
Blog
Dec 30, 2024, 04:50
Improved survival rates for veterans with de novo mHSPC - Prostate Cancer Foundation